Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: InspireMD is a medical device company developing the CGuard™ stent platform for carotid artery disease. In June 2025, the company received FDA PMA approval and CE Mark approval for its next-generation CGuard Prime system, officially launching commercial sales in the U.S. in July 2025. Operations and manufacturing are primarily based in Israel, with a new global headquarters established in Miami, Florida.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenues | $1,778 | $1,739 | $3,307 | $3,250 |
| Gross Profit | $313 | $331 | $605 | $623 |
| Gross Margin | 17.6% | 19.0% | 18.3% | 19.2% |
| Operating Expenses | $13,332 | $8,591 | $25,084 | $16,297 |
| Net Loss | $(13,151) | $(7,909) | $(24,317) | $(14,941) |
| Cash & Equivalents (End of Period) | $11,509 (as of June 30, 2025) | |||
| Marketable Securities | $7,865 (as of June 30, 2025) | |||
| Accumulated Deficit | $(277,823) (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased slightly by 2.3% in Q2 and 1.8% YTD compared to 2024, driven by adoption in Latin America and Asia, offset by decreases in Europe due to distributor inventory management ahead of the CGuard Prime launch.
- Expense Surge: Operating expenses increased significantly. Selling and Marketing expenses rose 188.7% in Q2 (to $4.17M) and 158.1% YTD due to building the U.S. commercial infrastructure. R&D expenses increased 12.7% in Q2 and 31.0% YTD, driven by SwitchGuard NPS development and U.S. hiring.
- Net Loss Expansion: Net loss widened by 66.3% in Q2 and 62.8% YTD, primarily due to the substantial increase in operating expenses.
- Liquidity Position: Cash and cash equivalents decreased from $18.9M at year-end 2024 to $11.5M at June 30, 2025. Net cash used in operating activities increased to $17.1M for the six months ended June 30, 2025.
Outlook, Risks, and Subsequent Events
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional financing, citing an accumulated deficit of $278M and negative operating cash flows.
- Subsequent Financing: On July 30, 2025, the company raised approximately $40.1 million in gross proceeds through a private placement of common stock and pre-funded warrants. Additionally, Series I warrants were exercised for approximately $15.9 million in proceeds subsequent to the balance sheet date.
- Geopolitical Risks: The company faces significant risks due to its manufacturing and operations in Israel. While a ceasefire was reached in June 2025, the situation remains volatile. The company relies entirely on Israeli manufacturing for the U.S. market until a transition to a U.S. contract manufacturer (Aptyx) is complete.
- Regulatory Milestones: The company successfully secured FDA PMA approval for CGuard Prime in June 2025 and initiated commercial launch in the U.S. in July 2025.
Investor Verification Checklist
- Capital Runway: Verify the net proceeds from the July 2025 private placement ($40.1M) and subsequent warrant exercises against the company's burn rate to assess the extension of the operating runway.
- Manufacturing Transition: Monitor the timeline and progress of transferring manufacturing from Israel to the U.S. facility with Aptyx to mitigate geopolitical and tariff risks.
- Commercial Execution: Track early U.S. sales performance of the CGuard Prime system following the July 2025 launch to validate revenue growth assumptions.
- Dilution Impact: Review the impact of the recent equity issuance and outstanding warrants (approx. 38.4M shares) on future earnings per share and ownership dilution.
- Geopolitical Exposure: Assess the potential for supply chain disruptions or increased costs due to ongoing regional instability in the Middle East.